177 related articles for article (PubMed ID: 23287011)
1. Smad7 antisense oligonucleotide-based therapy for inflammatory bowel diseases.
Zorzi F; Angelucci E; Sedda S; Pallone F; Monteleone G
Dig Liver Dis; 2013 Jul; 45(7):552-5. PubMed ID: 23287011
[TBL] [Abstract][Full Text] [Related]
2. Role of Smad7 in inflammatory bowel diseases.
Monteleone G; Caruso R; Pallone F
World J Gastroenterol; 2012 Oct; 18(40):5664-8. PubMed ID: 23155305
[TBL] [Abstract][Full Text] [Related]
3. TGF-Beta signaling manipulation as potential therapy for IBD.
Marafini I; Zorzi F; Codazza S; Pallone F; Monteleone G
Curr Drug Targets; 2013 Nov; 14(12):1400-4. PubMed ID: 23489130
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis.
Boirivant M; Pallone F; Di Giacinto C; Fina D; Monteleone I; Marinaro M; Caruso R; Colantoni A; Palmieri G; Sanchez M; Strober W; MacDonald TT; Monteleone G
Gastroenterology; 2006 Dec; 131(6):1786-98. PubMed ID: 17087939
[TBL] [Abstract][Full Text] [Related]
5. TGF-beta1 and Smad7 in the regulation of IBD.
Monteleone G; Boirivant M; Pallone F; MacDonald TT
Mucosal Immunol; 2008 Nov; 1 Suppl 1():S50-3. PubMed ID: 19079231
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Smad7 in Inflammatory Diseases of the Gut and Colon Cancer.
Troncone E; Marafini I; Stolfi C; Monteleone G
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920230
[TBL] [Abstract][Full Text] [Related]
7. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease.
Monteleone G; Kumberova A; Croft NM; McKenzie C; Steer HW; MacDonald TT
J Clin Invest; 2001 Aug; 108(4):601-9. PubMed ID: 11518734
[TBL] [Abstract][Full Text] [Related]
8. Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases.
Laudisi F; Dinallo V; Di Fusco D; Monteleone G
Curr Drug Metab; 2016; 17(3):303-6. PubMed ID: 26651974
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of Smad7 With a Specific Antisense Oligonucleotide Attenuates Colitis and Colitis-Driven Colonic Fibrosis in Mice.
Izzo R; Bevivino G; De Simone V; Sedda S; Monteleone I; Marafini I; Di Giovangiulio M; Rizzo A; Franzè E; Colantoni A; Ortenzi A; Monteleone G
Inflamm Bowel Dis; 2018 May; 24(6):1213-1224. PubMed ID: 29668937
[TBL] [Abstract][Full Text] [Related]
10. The TGF-β/Smad System in IBD Pathogenesis.
Sedda S; Marafini I; Dinallo V; Di Fusco D; Monteleone G
Inflamm Bowel Dis; 2015 Dec; 21(12):2921-5. PubMed ID: 26230862
[TBL] [Abstract][Full Text] [Related]
11. Smad7 Knockdown Restores Aryl Hydrocarbon Receptor-mediated Protective Signals in the Gut.
Monteleone I; Marafini I; Zorzi F; Di Fusco D; Dinallo V; Rizzo A; Sileri P; Sica G; Monteleone G
J Crohns Colitis; 2016 Jun; 10(6):670-7. PubMed ID: 26818761
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease.
Zorzi F; Calabrese E; Monteleone I; Fantini M; Onali S; Biancone L; Pallone F; Monteleone G
Aliment Pharmacol Ther; 2012 Nov; 36(9):850-7. PubMed ID: 22971085
[TBL] [Abstract][Full Text] [Related]
13. Activation of extracellular signal-regulated kinase by TGF-beta1 via TbetaRII and Smad7 dependent mechanisms in human bronchial epithelial BEP2D cells.
Huo YY; Hu YC; He XR; Wang Y; Song BQ; Zhou PK; Zhu MX; Li G; Wu DC
Cell Biol Toxicol; 2007 Mar; 23(2):113-28. PubMed ID: 17096210
[TBL] [Abstract][Full Text] [Related]
14. TGF-β1 signaling and Smad7 control T-cell responses in health and immune-mediated disorders.
Laudisi F; Stolfi C; Monteleone I; Monteleone G
Eur J Immunol; 2023 Nov; 53(11):e2350460. PubMed ID: 37611637
[TBL] [Abstract][Full Text] [Related]
15. High Smad7 sustains inflammatory cytokine response in refractory coeliac disease.
Sedda S; De Simone V; Marafini I; Bevivino G; Izzo R; Paoluzi OA; Colantoni A; Ortenzi A; Giuffrida P; Corazza GR; Vanoli A; Di Sabatino A; Pallone F; Monteleone G
Immunology; 2017 Mar; 150(3):356-363. PubMed ID: 27861825
[TBL] [Abstract][Full Text] [Related]
16. Oligonucleotide-Based Therapies for Inflammatory Bowel Disease.
Bevivino G; Sedda S; Marafini I; Monteleone G
BioDrugs; 2018 Aug; 32(4):331-338. PubMed ID: 29948918
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal Regulation Between Smad7 and Sirt1 in the Gut.
Sedda S; Franzè E; Bevivino G; Di Giovangiulio M; Rizzo A; Colantoni A; Ortenzi A; Grasso E; Giannelli M; Sica GS; Fantini MC; Monteleone G
Front Immunol; 2018; 9():1854. PubMed ID: 30147698
[TBL] [Abstract][Full Text] [Related]
18. Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's disease.
Ardizzone S; Bevivino G; Monteleone G
Therap Adv Gastroenterol; 2016 Jul; 9(4):527-32. PubMed ID: 27366221
[TBL] [Abstract][Full Text] [Related]
19. Transforming Growth Factor-β1/Smad7 in Intestinal Immunity, Inflammation, and Cancer.
Troncone E; Marafini I; Stolfi C; Monteleone G
Front Immunol; 2018; 9():1407. PubMed ID: 29973939
[TBL] [Abstract][Full Text] [Related]
20. Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease.
Monteleone G; Del Vecchio Blanco G; Monteleone I; Fina D; Caruso R; Gioia V; Ballerini S; Federici G; Bernardini S; Pallone F; MacDonald TT
Gastroenterology; 2005 Nov; 129(5):1420-9. PubMed ID: 16285943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
